Pasithea Therapeutics
KTTA
7 hedge funds and large institutions have $1.09M invested in Pasithea Therapeutics in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
75% more funds holding
Funds holding: 4 → 7 (+3)
0.02% less ownership
Funds ownership: 0.16% → 0.14% (-0.02%)
14% less capital invested
Capital invested by funds: $1.26M → $1.09M (-$178K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.43M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$71.6K |
| 3 |
HF
HRT Financial
New York
|
+$33.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33K |
| 5 |
BlackRock
New York
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$1.22M |
| 2 |
TSS
Two Sigma Securities
New York
|
-$32K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KPF
1
K2 Principal Fund
Toronto,
Ontario, Canada
| $973K | +$1.43M | +27,500 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $52K | +$71.6K | +1,377 | +1,497% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $22K | +$33K | +635 | New |
|
|
HF
4
HRT Financial
New York
| $22K | +$33.1K | +637 | New |
|
|
5
BlackRock
New York
| $15K | +$22.1K | +425 | New |
|
6
JP Morgan Chase
New York
| $2K | +$2.6K | +50 | New |
|
|
KC
7
Kepos Capital
New York
| – | -$1.22M | -20,000 | Closed |
|
|
TSS
8
Two Sigma Securities
New York
| – | -$32K | -522 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$10K | -165 | Closed |
|
10
Wells Fargo
San Francisco,
California
| – | +$104 | +2 | New |
|
KTTA Hedge Fund Activity: Q4 2021 in Review
7 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2021, worth a combined $1.09M — down 14% from $1.26M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KTTA positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was K2 Principal Fund, opening a new position worth an estimated $1.43M. The largest seller was Kepos Capital, exiting entirely with an estimated $1.22M sold.
- 7 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2021, up from 4 in Q3 2021.
- Funds reported $1.09M of Pasithea Therapeutics stock for Q4 2021, down 14% quarter-over-quarter.
- 6 funds opened new Pasithea Therapeutics positions in Q4 2021 and 3 closed out, a net change of +3 holders.
- The largest Pasithea Therapeutics buyer in Q4 2021 was K2 Principal Fund, an estimated $1.43M added.
- The largest Pasithea Therapeutics seller in Q4 2021 was Kepos Capital, an estimated $1.22M sold.
Based on aggregated 13F filings for Q4 2021.